Clinical Research Directory
Browse clinical research sites, groups, and studies.
Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial
Sponsor: Mount Sinai Hospital, Canada
Summary
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.
Official title: Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
118
Start Date
2025-01-03
Completion Date
2027-01
Last Updated
2025-01-24
Healthy Volunteers
No
Conditions
Interventions
Nirmatrelvir/ritonavir
Paxlovid PO BID for 5 days + standard of care
Remdesivir
Veklury IV daily for 5 days + standard of care
Locations (4)
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Niagara Health System
St. Catharines, Ontario, Canada
Mount Sinai Hospital, Sinai Health System
Toronto, Ontario, Canada
St. Joseph's Health Centre, Unity Health Toronto
Toronto, Ontario, Canada